Quick Takeaways
- ARMISTICE CAPITAL, LLC filed SCHEDULE 13G for XORTX Therapeutics Inc. Common shares, no par value per share (XRTX).
- Disclosed ownership: 10%.
- Date of event: 31 Dec 2024.
ARMISTICE CAPITAL, LLC - 31 Dec 2024 SCHEDULE 13G Report for XORTX Therapeutics Inc. Common shares, no par value per share (XRTX)
- Filing Manager
- ARMISTICE CAPITAL, LLC
- Reporting Manager
- Armistice Capital, LLC
- Symbol
- XRTX
- Shares outstanding
- 3,471,542 shares
- Disclosed Ownership
- 346,807 shares
- Ownership
- 10%
- Form type
- SCHEDULE 13G
- Filing time
- 14 Feb 2025, 17:04:07 UTC
- Date of event
- 31 Dec 2024
- Next filing
- 15 May 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"ARMISTICE CAPITAL, LLC disclosed 10% ownership in XORTX Therapeutics Inc. Common shares, no par value per share (XRTX) on 31 Dec 2024."
What Changed
- No earlier schedule filing is available for direct comparison.
- Current filing was accepted on 14 Feb 2025, 17:04.
Why This Matters
- This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
- You can verify ownership claims directly against the original SEC filing.
Official SEC Source
Backed by Schedule 13D/13G
Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.
See Original FilingReporting Managers (2)
| Name | Ownership | Shares Owned | sole voting power | shared voting power | Signature | Title | CIK |
|---|---|---|---|---|---|---|---|
| Armistice Capital, LLC | 10% | 346,807 | 0 | 346,807 | /s/ Steven Boyd | Steven Boyd - Managing Member | |
| Steven Boyd | 10% | 346,807 | 0 | 346,807 | /s/ Steven Boyd | Steven Boyd |